Deferasirox + azacitidine

Deferasirox + azacitidine is a combination of two pharmaceutical agents used primarily in the management of myelodysplastic syndromes (MDS) and related hematological disorders. Deferasirox is an orally administered, once-daily iron chelator that binds excess iron, facilitating its excretion and reducing iron overload commonly seen in patients receiving chronic blood transfusions[3][5]. Azacitidine is a pyrimidine nucleoside analogue with antineoplastic activity; it acts as a hypomethylating agent by inhibiting DNA methyltransferase, leading to DNA hypomethylation and direct cytotoxicity against abnormal hematopoietic cells through incorporation into RNA and DNA[1][4][6]. The combination may be considered for MDS patients who require both disease-modifying therapy (azacitidine) and management of transfusional iron overload (deferasirox).

Brand names

VidazaExjadeJadenu

Other names

deferasiroxazacitidine